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Abstract
Background: Lgr5 has recently been identified as a reliable biomarker of cancer stem cells (CSCs) in colorectal
cancer (CRC); however, its prognostic value is still controversial.
Methods: We searched PubMed, Web of Science, and Wanfang databases with identical strategies to retrieve
articles. We evaluated the impact of Lgr5 expression on survival of CRC patients through meta-analysis.
Results: A total of 12 studies comprising 2600 patients revealed that Lgr5 overexpression was negatively associated
with overall survival (OS) (HR = 1.73, 95 % CI: 1.28–2.33; P = 0.00) and disease free survival (DFS) (HR = 2.89, 95 % CI:
1.89–4.44; P = 0.000) in CRC patients. Subgroup analysis suggested that Lgr5 overexpression was significantly
associated with worse OS in subgroups with IHC as the method of Lgr5 assessment (HR = 2.01, 95 % CI: 1.39–2.89;
P = 0.001), patients from Asia (HR = 1.81, 95 % CI: 1.27–2.58; P = 0.000), and NOS scores greater than 6 (HR = 2.12, 95 % CI:
1.41–3.19; P = 0.000). Furthermore, sensitivity analysis showed that the estimated HR ranged from 1.6 to 1.86 upon
excluding one study sequentially from each analysis. In addition, Lgr5 overexpression was significantly associated with
deep invasion of CRC (OR = 0.39, 95 % CI: 0.17–0.87; P = 0.002), lymphnode metastasis (OR = 0.45, 95 % CI: 0.26–0.76;
P = 0.003), distant metastasis (OR = 0.37, 95 % CI: 0.22–0.62; P = 0.000), and AJCC stage (OR = 0.35, 95 % CI: 0.15–0.78;
P = 0.01). However, Lgr5 overexpression was not correlated with tumor grade (OR = 0.75 95 % CI: 0.37–1.54; P = 0.433).
Conclusions: This study shows that Lgr5 can be a valuable and reliable prognostic factor of colorectal cancer
progression.
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Background
Colorectal cancer (CRC) is the third most common form
of cancer and the third leading cause of cancer-related
deaths in the United States [1]. Despite the enormous
progress that has been made in CRC treatment, the
overall mortality of CRC is still around 40 % [2]. Cur-
rently, TNM classification, including local tumor infiltra-
tion depth, lymph node involvement, and distant organ
metastasis, is the main criterion for identifying those pa-
tients who carry a high risk for disease relapse and poor
outcomes [3]. Unfortunately, 40–60 % of cases classified
as either stage II or stage III will relapse or develop
metastases following curative resection [4]. In addition,
patients can follow significantly different clinical courses
despite being diagnosed in the same stage. Therefore,
identification of novel prognostic factors to distinguish
high-risk groups is imperative for the improvement of
therapeutic approaches in CRC treatment.
Recent mounting evidence indicates that cancer stem
cells (CSCs) play a crucial role in tumor initiation, ther-
apy resistance, disease relapse, and tumor progression
[5–7]. A number of studies have demonstrated that ex-
pression of CSC markers in CRC have prognostic signifi-
cance [8, 9]. CD133 was initially identified as a biomarker
in primary CRC [10, 11] where it was believed to be widely
expressed in human primary colon cancer epithelial cells.
However, the CD133- subpopulation is now known to be
composed mostly of stromal and inflammatory cells [12]
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that possess the ability to initiate xenograft tumors. Alter-
natively, Leucine-rich repeat-containing G-protein-coupled
receptor 5 (Lgr5), a member of the G protein-coupled
receptor (GPCR) family of proteins, has recently been re-
ported as a reliable biomarker of CSCs in CRC [13]. Many
studies have demonstrated that Lgr5 protein is overex-
pressed in CRC and is associated with tumor initi-
ation, 5-FU-based chemotherapy resistance, and recurrence
[14–18]. Therefore, Lgr5 expression is thought to be a po-
tential biomarker related to poor prognosis in CRC. How-
ever, a recent, retrospective study comprising 891 colorectal
adenocarcinomas revealed that Lgr5 did not have prognos-
tic significance in CRC [19]. These contradictory results
highlight the need to systematically analyze the data of
Lgr5 expression in CRC to draw a reasonable conclusion
about its prognostic significance.
In this study, we performed a meta-analysis to explore
the association between Lgr5 expression and the prog-
nosis of CRC. The correlation of Lgr5 expression with
clinical-pathological features in CRC, such as tumor
grade and tumor stage, was also investigated.
Methods
Literature search
We searched PubMed, Web of Science, and Wanfang
databases using the following terms: “Lgr5”, “colorectal
neoplasms”, “colorectal cancer”, “colon cancer”, “rectal
cancer”, and “prognosis”. We also searched references
cited in retrieved articles to identify additional eligible
studies. The last search update was February 15th, 2014.
In studies with overlapping patients, the most inform-
ative one was chosen to avoid duplicate information.
Inclusion and exclusion criteria
The eligible studies included in our meta-analysis met
the following inclusion criteria: (1) evaluated the rela-
tionship between Lgr5 expression in human CRC sam-
ples and overall survival (OS), disease free survival
(DFS), or clinicopathological characteristics of CRC; (2)
provided sufficient data to calculate hazard ratios (HRs)
or odds ratios (ORs) and their 95 % confidence intervals
(CIs); (3) published in English or Chinese. The following
articles were excluded: (1) articles without original data
such as letters, case reports, reviews, or conference ab-
stracts; (2) articles published in a language other than
English or Chinese; (3) articles that lacked the necessary
data for estimating HRs or ORs and the corresponding
95 % CIs.
Data extraction and assessment of study quality
Two authors independently reviewed and extracted data
from each eligible study. Disagreements in data extrac-
tion were arbitrated by a third investigator. The follow-
ing data were retrieved from the studies: name of the
first author, year of publication, country of origin of the
patients, number of patients included in the study,
method used to detect Lgr5, cut-off value of Lgr5 ex-
pression, study design, clinicopathological features, and
survival data. The quality of each eligible study was
assessed according to the Newcastle–Ottawa quality as-
sessment scale.
Statistical analysis
To pool the survival data quantitatively, the impact of
Lgr5 overexpression on OS or DFS of patients with CRC
was evaluated by HRs with 95 % CIs. The HRs with
95 % CIs were estimated according to the methods re-
ported by Parmar [20]. We used the raw data directly if
HRs and their corresponding 95 % CIs were described in
the publication. Otherwise, the value of HRs with 95 % CIs
was estimated by other parameters, such as the O-E
statistic and variance. Also, Kaplan-Meier curves of
OS or DFS were read by Engauge Digitizer 4.1 (http://
digitizer.sourceforge.net/). ORs (odds ratios) with 95 %
CIs were used to determine the relationship between Lgr5
overexpression and clinicopathological parameters of CRC,
such as tumor grade, AJCC stage, depth of invasion, lymph
node metastasis, and distant metastasis. An observed HR >
1 and an observed OR < 1 indicated a worse prognosis for
survival and unfavorable parameters in patients that over-
expressed Lgr5. The impact of Lgr5 overexpression on sur-
vival or clinicopathological features was considered to be
statistically significant if the 95 % CI did not overlap with 1.
The heterogeneity that exists in a meta-analysis due to
the variation in outcomes between studies was evaluated
by Chi-square, according to Peto’s method [21]. The in-
consistency index (I2) statistic (range from 0 % to 100 %)
was used to quantify the percentage of total variation
across studies that is due to heterogeneity rather than
sampling error [22]. A P < 0.10 for the Q-test indicated
heterogeneity exists among the studies, then we used the
random-effects model (the DerSimonian and Laird
method) [22]. Otherwise, we adopted the fixed-effects
model (Mantel-Haenszel) to calculate the pooled ORs
and HRs [22]. Both the Begg’s test and Egger’s test were
used to determine publication bias where p < 0.05 indi-
cated bias. All calculations were performed using
STATA 12.0 software (Stata Corporation, Collage Station,
Texas, USA). A p-value < 0.05 was considered statistically
significant.
Results
Search results and description of the studies
Upon analysis of the title and abstract of 348 potential
studies that were retrieved using the search strategy de-
scribed above, we identified 129 articles involving the
survival risk of CRC and Lgr5 expression. Of these 129
studies, 42 did not offer sufficient data to calculate the
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HR or OR, three overlapped with other studies, and 72
did not involve clinical specimens resulting in a total of
twelve studies that were included in our meta-analysis
[14, 19, 23–32]. In addition, no another study was iden-
tified through searching references cited in retrieved ar-
ticles. A detailed search strategy is described in Fig. 1.
The characteristics of the nine eligible studies, which
were retrospective case–control studies published be-
tween 2010 and 2014, are summarized in Table 1. This
meta-analysis involved a total of 2600 CRC patients with
sample sizes ranging from 44 to 891 patients. Of the
twelve studies, seven evaluated patients from China,
three assessed patients from Japan,and one each exam-
ined patients from America and Spain. Furthermore,
four studies assessed the relationship between Lgr5 ex-
pression and DFS of CRC patients while ten studies eval-
uated the correlation between Lgr5 expression and OS
of CRC patients. With regards to the method of analysis,
nine studies assessed Lgr5 expression using immunohis-
tochemistry (IHC), two determined Lgr5 expression by
RT-PCR, and the remaining study evaluated Lgr5 ex-
pression through in situ hybridization (ISH).
Methodological quality of the studies
We assessed the quality of the 12 eligible case–control
studies according to the Newcastle–Ottawa Scale (NOS),
a method developed as a collaborative effort between the
Universities of Newcastle, Australia and Ottawa, Canada.
NOS scores were determined by judging the studies on
items in three general categories, including the selection
of the study populations, the comparability of the popu-
lations, and the ascertainment of either the exposure or
the outcome of interest. Scores ranged from 0 (lowest)
to 9 (highest), and studies with scores of 7 or more were
defined as high quality studies. The quality scores of
each study are summarized in Table 1. The median and
mean score of these 12 studies were 7 and 6.67, respect-
ively, indicating that they were of high quality.
Correlation of Lgr5 overexpression with decreased OS
and DFS in CRC
We performed a meta-analysis on ten studies to evaluate
the association between Lgr5 overexpression and OS
and a meta-analysis on four studies to determine the as-
sociation between Lgr5 overexpression and DFS. The
pooled hazard ratio (HR) for OS was 1.73 (95 % CI:
1.28–2.33; Z = 3.59; P = 0.00) (Fig. 2) with heterogeneity
(I2 77.5 % P = 0.00), indicating that the HR of overall
death was 1.73-fold higher in patients with increased
levels of Lgr5; the pooled HR for DFS was 2.89 (95 % CI:
1.89–4.44; Z = 4.89; P = 0.000) without heterogeneity (I2
0 % P = 0.708) (Fig. 2). These results suggest that Lgr5
overexpression is significantly correlated with a worse
prognosis in CRC patients.
Subgroup analysis and sensitivity analysis of the
relationship between Lgr5 overexpression and OS in CRC
We performed subgroup analysis and sensitivity analysis
in order to address the heterogeneity that was observed
in the correlation between Lgr5 overexpression and de-
creased OS in CRC patients. The characteristics that we
evaluated for the subgroup analysis were the following:
number of patients involved in the study, the country of
origin of the patients, the method used to determine
Lgr5 expression, and NOS scores of the study. Lgr5
overexpression was correlated with worse OS in
Fig. 1 Flow diagram of the selection procedure for the studies
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Table 1 Characteristics of the studies included for the meta-analysis
First author Year Country Patient (M/F) Age (year) Technology Lgr5 positive threshold HR (95 % CI)
of OS
HR (95 % CI)
of DFS
Quality score
Liu 2014 China 363 (200/166) 59mean IHC NA 2.604 (1.894–3.584) NA 7
He 2014 China 53 (29/24) NA IHC NA 2.482 (1.52–4.283) NA 7
Gao 2014 China 44 (22/20) 59median IHC The percentage of stained cells≥ 10 % 2.299 (0.922–5.714) NA 6
Wu 2012 China 192 (120/72) 62median IHC Multiplying the intensity and the quantity score > 5 2.768 (1.619–4.732) NA 8
Hsu 2013 China 296 (169/127) 63.5mean IHC The percentage of stained cells multiplied by the
intensity scores ≥180
NA 2.21 (1.11–4.37) 7
Saiqusa 2012 Japan 52 (41/11) 64.5median IHC The percentage of stained cells ≥ 50 % 1.061 (0.299–3.771) 4.942 (1.39–17.577) 6
Ziskin 2012 America 891 (467/424) 71.4mean ISH Intensity score >1 1.15 (0.95–1.4) NA 7
Valladares-Ayerbes 2012 Spain 54 (33/21) 62.7mean QRT-PCR 11.6 2.517 (0.924–6.858) 2.995 (1.192–7.527) 8
Takahashi 2011 Japan 180 (105/75) NA QRT-PCR Median value 0.909 (0.535–1.543) 3.3 (1.49–7.33) 6
Bao 2012 China 246 (131/115) 63mean IHC The percentage of stained cells≥ 5 % 1.122 (0.866–1.448) NA 4
Peng 2010 China 169 (101/68) 57mean IHC The percentage of stained cells≥ 10 % 2.16 (1.35–3.45) NA 7











subgroups with patients from Asia (HR = 1.81, 95 % CI:
1.27–2.58; P = 0.000), IHC as a method of Lgr5 assessment
(HR = 2.01, 95 % CI: 1.39–2.89; P = 0.001), and NOS scores
greater than 6 (HR = 2.12, 95 % CI: 1.41–3.19; P = 0.000)
(Fig. 3) (Table 2). We also conducted a sensitivity analysis
to evaluate the effect of a single study on the overall esti-
mate by sequentially excluding each study, as outlined in
Table 2. Upon omitting each of the indicated studies, the
estimated HR ranged from 1.6 to 1.86 (Table 3).
Impact of Lgr5 overexpression on clinicopathological
features of CRC
Next, we examined the relationship between Lgr5 overex-
pression and several clinicopathological parameters of CRC
(Fig. 4). Lgr5 overexpression appeared to be significantly
associated with deep invasion of CRC (OR= 0.39, 95 % CI:
0.17–0.87; P = 0.002), lymph node metastasis (OR = 0.45,
95 % CI: 0.26–0.76; P = 0.003), distant metastasis (OR =
0.37, 95 % CI: 0.22–0.62; P = 0.000), and AJCC stage (OR =
0.35, 95 % CI: 0.15–0.78; P = 0.01). (Figure 4); however, it
was not correlated with tumor grade (OR = 0.75 95 % CI:
0.37–1.54; P = 0.433).
Publication bias
We assessed the potential publication bias both graphic-
ally, through funnel plots of the Egger’s test on OS
(Fig. 5), and statistically, by the Egger’s and Begg’s test.
The symmetry of the funnel plots and the p-values from
the statistical analysis suggest no publication bias.
(Lgr5-negtive vs Lgr5-positive )
Overall survival
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Fig. 2 Hazard ratio (HR) of Lgr5 overexpression associated with (a) overall survival (OS) and (b) disease free survival (DFS)
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Fig. 3 Hazard ratio (HR) of Lgr5 overexpression associated with overall survival (OS) in the subgroup of (a) patient sample size, (b) NOS score of
study, (c) the Lgr5 assessment method, and (d) patients’ country of origin
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Discussion
Lgr5, also known as GPR49, has been reported to be a
reliable biomarker of CSCs in CRC [13]. Overexpression
of Lgr5, through an in vitro assay, resulted in enhanced
proliferation and resistance to chemotherapy [14, 18].
Consistent with these results, Lgr5 ablation in CRC cell
lines inhibited cell growth, enhanced apoptosis, and in-
creased the sensitivity of cells to chemotherapy [14]. The
close relationship between Lgr5 and Ki-67 further sup-
ports the correlation between Lgr5 overexpression and
increased proliferative capability [23]. Furthermore, Lgr5
was recently shown to be involved in the carcinogenesis of
CRC as a target of the Wnt signaling pathway [33, 34].
Despite these data, the relationship between Lgr5 expres-
sion and prognosis of CRC is still not completely
understood and Lgr5, as a useful biomarker associated
with poor prognosis in CRC, still remains controversial.
Therefore, in this study, we performed a meta-analysis to
systematically evaluate the association between Lgr5 ex-
pression and the prognosis of CRC.
Previous studies reported that Lgr5 was overexpressed
in human colon tumors, as compared to normal colon tis-
sues [16]. Lgr5 expression was also significantly correlated
with worse prognosis in 192 CRC patients by immunohis-
tochemistry [23]. Consistent with these findings, our
meta-analysis demonstrated that elevated Lgr5 expression
was negatively associated with OS and DFS in CRC pa-
tients, suggesting an important role for Lgr5 in tumor
progression. Subgroup analysis further distinguished that
Lgr5 overexpression was correlated with worse OS when
Table 2 Subgroup analysis of pooled hazard ratios of colorectal patients with Lgr5 overexpression
Heterogeneity
Stratified analysis Number of studies Number of patients Pooled HR (95 % CI) P value I2(%) P value Interaction p value
Study location 0.518
Asia 8 1299 1.81 (1.27–2.58) 0.001 76.2 0.000
Europe and America 2 945 1.45 (0.72–2.92) 0.299 55.8 0.133
Number of patients 0.38
>100 6 2041 1.6 (1.12–2.29) 0.01 85 0.043
<100 4 203 2.26 (1.53–3.34) 0.000 0 0.673
Method of measurement 0.15
IHC 7 1119 2.01 (1.39–2.89) 0.000 74.6 0.001
ISH 1 891 1.15 (0.95–1.4) 0.158
qRT-PCR 2 234 1.38 (0.52–3.68) 0.521 67.8 0.078
NOS score 0.055
>6 6 1669 2.12 (1.41–3.19) 0.000 82.8 0.000
≦6 4 575 1.13 (0.9–1.4) 0.291 55.9 0.393
Table 3 Meta sensitivity analysis of Lgr5 expression and OS
Study omitted Estimated HR Low value
of 95 % CI
High value
of 95 % CI
Wu (2012) [23] 1.6325674 1.2023937 2.2166421
Saiqusa (2012) [24] 1.7648035 1.295853 2.4034605
Ziskin (2012) 1.8513726 1.3232487 2.5902767
Valladares-Ayerbes (2012) [25] 1.6885946 1.2394606 2.300478
Takahashi (2011) [26] 1.8601217 1.3568895 2.5499887
Bao (2012) [29] 1.8537774 1.3164659 2.6103909
Peng (2010) [28] 1.6803607 1.2180028 2.3182311
Liu (2014) [32] 1.6021169 1.2043179 2.1313131
He (2014) [31] 1.6534556 1.2091391 2.2610431
Gao (2014) [30] 1.6943128 1.2407216 2.3137312
Combined 1.7265576 1.2812517 2.3266318
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patients from Asia,IHC as a method of Lgr5 assessment
and NOS scores were greater than 6. The outcome of the
sensitivity analysis corroborated the relationship between
Lgr5 overexpression and worse OS in CRC patients. Fur-
thermore, several studies showed that the expression of
Lgr5 was up-regulated in advanced CRC [14, 17, 26]. The
relationship between Lgr5 expression and clinicopatholog-
ical parameters was analyzed, and the results showed that
Lgr5 overexpression was significantly correlated with deep
invasion, lymph node metastasis,distant metastasis, and
advanced AJCC stage. These results suggest that Lgr5 ex-
pression could serve as a valuable prognostic factor for
CRC patients.
However, inevitably, some limitations exist in our
meta-analysis. First, although random effects model was
used to deal with heterogeneity, the inter-study hetero-
geneity caused by the use of different populations, vary-
ing detection methods, and different cutoff values was
inevitable. Second, the number of studies included in
subgroup analysis according to country and measure-
ment method was relatively small, it may result in bias
and further studies will need to be performed in order
to confirm and strengthen these results. Finally, the re-
sults of retrospective case–control studies in our meta-
analysis were less reliable than that of prospective cohort
studies or randomized controlled trials.
A B
C D
Fig. 4 Odds ratio (OR) of Lgr5 overexpression associated with clinicopathological features of colorectal cancer. a The pooled OR and its
corresponding 95 % CI of Lgr5 overexpression with AJCC stage. b The pooled OR and its corresponding 95 % CI of Lgr5 overexpression with
primary tumor. c The pooled OR and its corresponding 95 % CI of Lgr5 overexpression with lymph node metastasis. d The pooled OR and its
corresponding 95 % CI of Lgr5 overexpression with distant metastasis
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Conclusion
In conclusion, our results show that Lgr5 overexpression
is significantly associated with poor OS as well as DFS of
CRC patients. Furthermore, advanced AJCC stage, deep
invasion, and distant metastasis seems to be more fre-
quent in patients that overexpress Lgr5. Therefore, Lgr5
overexpression appears to be a valuable prognostic fac-
tor and a reliable indicator of CRC progression.
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